ArticleNature biotechnology2020
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 109 papers.
0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 261 citations in OpenAlex.
- Streamlined stable CHO cell line development using droplet microfluidics with image-based monoclonality assessment.Bioprocess and biosystems engineering · 2026Article
- Rapid discovery of monoclonal antibodies via high-throughput single BCR affinity sequencing.Nucleic acids research · 2026Article
- Optimization and Parallelization of Sorting by Interfacial Tension (SIFT) for High-Throughput Metabolic Cell Sorting.Micromachines · 2026Article
- Cell assays in microcompartments driven by droplet microfluidics and hydrogel technologies.Journal of biochemistry · 2026Review
- From Single Cells to Silicon: Emerging Technologies Transforming Monoclonal Antibody Discovery.Antibodies (Basel, Switzerland) · 2026Review
- Genuine Directed Evolution In Test Tube (GENie).bioRxiv : the preprint server for biology · 2026Article
- The adaptive immune receptors in a big data world.ImmunoHorizons · 2026Review
- PiP-Plex: A Particle-in-Particle System for Multiplexed Quantification of Proteins Secreted by Single Cells.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Paraplume: A fast and accurate antibody paratope prediction method provides insights into repertoire-scale binding dynamics.PLoS computational biology · 2026Article
- Rapid immunization and antibody redesign platform discovers broadly neutralizing antibodies against non-immunized SARS-CoV-2 variant.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies.Scientific reports · 2026Article
- Cell-free immuno-profiling on a genetically programmed biochip.Nature nanotechnology · 2026Article
- Enhancing large particle recovery in high-throughput functional cell sorting through ΔBOP optimization.Scientific reports · 2025Article
- Engineering mammalian protein secretion: Toward the convergence of high-throughput biology and computational methods.Cell systems · 2025Review
- Deterministic Co-encapsulation of Microparticles in Droplets via Synchronized Merging for Single-Cell Genomics.Analytical chemistry · 2025Article
- Detection and Validation of Influenza Virus Hemagglutinin Specific, Cross-Reactive, and Heteroclitic B Cells Induced by a Combination Vaccine Adjuvant.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2025Article
- Article
- Integration of hyperspectral imaging and transcriptomics from individual cells with SpectralSeq.Genome research · 2025Article
- Recent Advances in Antibody Discovery Using Ultrahigh-Throughput Droplet Microfluidics: Challenges and Future Perspectives.Biosensors · 2025Review
- A Versatile High-Throughput Single-Cell Screening Platform for Profiling Antigen-Specific Long-Lived B Cells in Blood and Bone Marrow.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
37 authors at 6 institutions in 5 countries.
Annabelle GérardHiFiBiO Therapeutics SAS, Paris, France.ORCID http://orcid.org/0000-0003-0411-768X
Adam Woolfe *HiFiBiO Therapeutics SAS, Paris, France.
Guillaume Mottet *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Marcel Reichen *HiFiBiO Therapeutics SAS, Paris, France.
Carlos Castrillon *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.ORCID http://orcid.org/0000-0003-2909-7371
Vera Menrath *HiFiBiO Therapeutics SAS, Paris, France.
Sami Ellouze *HiFiBiO Therapeutics SAS, Paris, France.
Adeline Poitou *HiFiBiO Therapeutics SAS, Paris, France.
Raphaël Doineau *HiFiBiO Therapeutics SAS, Paris, France.ORCID http://orcid.org/0000-0003-0817-7778
Luis Briseno-RoaHiFiBiO Therapeutics SAS, Paris, France.
Pablo Canales-HerreriasUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.ORCID http://orcid.org/0000-0002-1865-6476
Pascaline MaryHiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Gregory RoseHiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Charina OrtegaHiFiBiO Therapeutics Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-8814-8629
Matthieu DelincéHiFiBiO Therapeutics Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8052-7918
Sosthene EssonoHiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Bin JiaPfizer, Cambridge, MA, USA.
Bruno IannascoliUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Odile Richard-Le GoffUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Roshan KumarHiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Samantha N StewartHiFiBiO Therapeutics Inc., Cambridge, MA, USA.
Yannick PousseHiFiBiO Therapeutics SAS, Paris, France.
Bingqing ShenHiFiBiO Therapeutics SAS, Paris, France.
Kevin GrosselinHiFiBiO Therapeutics SAS, Paris, France.
Baptiste SaudemontUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.
Antoine Sautel-CailléLaboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.ORCID http://orcid.org/0000-0003-3899-3020
Alexei GodinaLaboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.
Scott McNamaraHiFiBiO Therapeutics SAS, Paris, France.
Klaus EyerLaboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.ORCID http://orcid.org/0000-0001-9344-5110
Gaël A MillotInstitut Pasteur, Hub Bioinformatique et Biostatistique, C3BI, USR 3756 IP CNRS, Paris, France.ORCID http://orcid.org/0000-0002-0591-3509
Jean BaudryLaboratoire Colloïdes et Matériaux Divisés (LCMD), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.ORCID http://orcid.org/0000-0002-5526-499X
Patrick EnglandPlateforme de Biophysique Moléculaire, Institut Pasteur, CNRS UMR3528, Paris, France.
Clément NizakLaboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France.ORCID http://orcid.org/0000-0002-4591-8240
Allan JensenHiFiBiO Therapeutics SAS, Paris, France.
Andrew D GriffithsLaboratoire de Biochimie (LBC), ESPCI Paris, PSL Research University, CNRS UMR8231 Chimie Biologie Innovation, Paris, France. andrew.griffiths@espci.fr.ORCID http://orcid.org/0000-0002-0808-3539
Pierre BruhnsUnit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France. pierre.bruhns@pasteur.fr.ORCID http://orcid.org/0000-0002-4709-8936
Colin BrenanHiFiBiO Therapeutics SAS, Paris, France. c.brenan@1cell-bio.com.ORCID http://orcid.org/0000-0002-9570-6166
Centre National de la Recherche Scientifique · FRHiFiBiO Therapeutics (France) · FRHiFiBiO Therapeutics (United States) · USInserm · FRLundbeck (Denmark) · DKPfizer (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes
Indexed as
High-Throughput Nucleotide SequencingSingle-Cell AnalysisAnimalsAntibodiesAntigensB-LymphocytesCancer VaccinesDNAHumansImmunoglobulin GMiceMicrofluidic Analytical TechniquesAntibodiesAntigensCancer VaccinesDNAImmunoglobulin G
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.